

32nd Ernst Klenk Symposium in Molecular Medicine

Precision oncology: Translating basic discoveries into patient survival.

Dec. 08 - 10, 2016

Program

Scientific Coordinator

Charles Swanton The Francis Crick Institute - London, UK jointly with Christian Reinhardt and Roman Thomas Chairs of the Cologne Ernst Klenk Symposium Committee 2016

Reinhardt Büttner - Michal-Ruth Schweiger - Michael Hallek - Wilhelm Stoffel - D. Grosskopf-Kroiher - Thomas Benzing

in association with

<u>Center for Integrated Oncology • KFO 286 • CRC 829 • CRC 670 • Dept. of Translational Genomics •</u> <u>e:Med Systems Medicine</u> • <u>sybacol • ITN CodeAge</u> • <u>CECAD Cologne</u> • <u>Cologne Center for Genomics •</u> <u>Dept. for Pathology • Dept. I for Internal Medicine • Clinical Trials Centre Cologne • University Hospital</u> <u>Cologne • EMTRAIN • ORPHEUS • BioRiver - Life Science im Rheinland e.V.</u> <u>Cologne Convention Bureau</u>

Participation in the meeting is free of charge. Further information and free registration: http://www.zmmk.uni-koeln.de/events/ernst klenk symposium/klenk 2016/index eng.html

Invitation for Poster Presentation

Venue

Main Lecture Hall of the Centers for Biochemistry and Physiology Medical Faculty, University of Cologne, Joseph-Stelzmann-Str. 52b, 50931 Cologne

Organization

Center for Molecular Medicine Cologne (CMMC), University of Cologne

12.50 p.m. Welcome Address: Thomas Krieg Dean - Medical Faculty, University of Cologne Thomas Benzing Chair - Center for Molecular Medicine Cologne, University of Cologne Charles Swanton - Christian Reinhardt - Roman Thomas Scientific Coordinators - Ernst Klenk Symposium 2016 Session I Discovering basic principles of actionable genomic aberrations in cancer/tumor evolution/acquired resistance Chairs Charles Swanton (The Francis Crick Institute - London, UK) 1.00 - 1.30 p.m. Molecular targets in childhood malignancies Stefan Pfister - German Cancer Research Center - Heidelberg, GER 1.30 - 2.00 p.m. A landscape of pharmacogenomic interactions in cancer Mathew Garnett - Wellcome Trust Sanger Institute - Cambridge, UK 2.00 - 2.30 p.m. Targeting non BRAFY®® Melanoma Jeffrey A Sosman - Vanderbilt-Ingram Cancer Center, Vanderbilt Univ. Medical Center - Nashville, USA 3.30 - 3.00 p.m. Cheires Break 3.00 - 3.30 p.m. Therapy of lymphoma inspired by functional and structural genomics Louis M Staudt - National Cancer Institute, Center for Cancer Research - Bethesda, USA 3.30 - 4.00 p.m. Pending Neal Rosen - Dept. of Medicine, Memorial Sloan Kettering Cancer Center - New York, USA 4.00 - 4.30 p.m. The development of next generation cancer therapeutics William R Sellers - Novartis Institutes of BioMedical Research - Cambridge, USA 4.30 - 5.00 p.m. Coffee Break 5.00 - 8.30 p.m. Poster session incl. selection of three post		
Construction cancer/tumor evolution/acquired resistance Chairs Charles Swanton (The Francis Crick Institute - London, UK) 1.00 - 1.30 p.m. Molecular targets in childhood malignancies Stefan Pfister - German Cancer Research Center - Heidelberg, GER 1.30 - 2.00 p.m. A landscape of pharmacogenomic interactions in cancer Mathew Garnett - Wellcome Trust Sanger Institute - Cambridge, UK 2.00 - 2.30 p.m. Targeting non BRAF ^{v600} Melanoma Jeffrey A Sosman - Vanderbilt-Ingram Cancer Center, Vanderbilt Univ. Medical Center - Nashville, USA 2.30 - 3.00 p.m. Coffee Break 3.00 - 3.30 p.m. Therapy of lymphoma inspired by functional and structural genomics Louis M Staudt - National Cancer Institute, Center for Cancer Research - Bethesda, USA 3.30 - 4.00 p.m. Pending Neal Rosen - Dept. of Medicine, Memorial Sloan Kettering Cancer Center - New York, USA 4.00 - 4.30 p.m. The development of next generation cancer therapeutics William R Sellers - Novartis Institutes of BioMedical Research - Cambridge, USA 4.30 - 5.00 p.m. Coffee Break 5.00 - 8.30 p.m. Poster session	12.50 p.m.	Thomas KriegDean - Medical Faculty, University of CologneThomas BenzingChair - Center for Molecular Medicine Cologne, University of CologneCharles Swanton - Christian Reinhardt - Roman Thomas
 1.00 - 1.30 p.m. Molecular targets in childhood malignancies Stefan Pfister - German Cancer Research Center - Heidelberg, GER 1.30 - 2.00 p.m. A landscape of pharmacogenomic interactions in cancer Mathew Garnett - Wellcome Trust Sanger Institute - Cambridge, UK 2.00 - 2.30 p.m. Targeting non BRAF^{v600} Melanoma Jeffrey A Sosman - Vanderbilt-Ingram Cancer Center, Vanderbilt Univ. Medical Center - Nashville, USA 2.30 - 3.00 p.m. Coffee Break 3.00 - 3.30 p.m. Therapy of lymphoma inspired by functional and structural genomics Louis M Staudt - National Cancer Institute, Center for Cancer Research - Bethesda, USA 3.30 - 4.00 p.m. Pending Neal Rosen - Dept. of Medicine, Memorial Sloan Kettering Cancer Center - New York, USA 4.00 - 4.30 p.m. The development of next generation cancer therapeutics William R Sellers - Novartis Institutes of BioMedical Research - Cambridge, USA 4.30 - 5.00 p.m. Coffee Break 5.00 - 8.30 p.m. Poster session 	Session I	
 Stefan Pfister - German Cancer Research Center - Heidelberg, GER 1.30 - 2.00 p.m. A landscape of pharmacogenomic interactions in cancer Mathew Garnett - Wellcome Trust Sanger Institute - Cambridge, UK 2.00 - 2.30 p.m. Targeting non BRAF^{v600} Melanoma Jeffrey A Sosman - Vanderbilt-Ingram Cancer Center, Vanderbilt Univ. Medical Center - Nashville, USA 2.30 - 3.00 p.m. Coffee Break 3.00 - 3.30 p.m. Therapy of lymphoma inspired by functional and structural genomics Louis M Staudt - National Cancer Institute, Center for Cancer Research - Bethesda, USA 3.30 - 4.00 p.m. Pending Neal Rosen - Dept. of Medicine, Memorial Sloan Kettering Cancer Center - New York, USA 4.00 - 4.30 p.m. The development of next generation cancer therapeutics William R Sellers - Novartis Institutes of BioMedical Research - Cambridge, USA 4.30 - 5.00 p.m. Coffee Break 5.00 - 8.30 p.m. Poster session 	Chairs	Charles Swanton (The Francis Crick Institute - London, UK)
 Mathew Garnett - Wellcome Trust Sanger Institute - Cambridge, UK 2.00 - 2.30 p.m. Targeting non BRAF^{V600} Melanoma Jeffrey A Sosman - Vanderbilt-Ingram Cancer Center, Vanderbilt Univ. Medical Center - Nashville, USA 2.30 - 3.00 p.m. Coffee Break 3.00 - 3.30 p.m. Therapy of lymphoma inspired by functional and structural genomics Louis M Staudt - National Cancer Institute, Center for Cancer Research - Bethesda, USA 3.30 - 4.00 p.m. Pending Neal Rosen - Dept. of Medicine, Memorial Sloan Kettering Cancer Center - New York, USA 4.00 - 4.30 p.m. The development of next generation cancer therapeutics William R Sellers - Novartis Institutes of BioMedical Research - Cambridge, USA 4.30 - 5.00 p.m. Coffee Break 5.00 - 8.30 p.m. Poster session 	1.00 - 1.30 p.m.	
 Jeffrey A Sosman - Vanderbilt-Ingram Cancer Center, Vanderbilt Univ. Medical Center - Nashville, USA 2.30 - 3.00 p.m. Coffee Break 3.00 - 3.30 p.m. Therapy of lymphoma inspired by functional and structural genomics Louis M Staudt - National Cancer Institute, Center for Cancer Research - Bethesda, USA 3.30 - 4.00 p.m. Pending Neal Rosen - Dept. of Medicine, Memorial Sloan Kettering Cancer Center - New York, USA 4.00 - 4.30 p.m. The development of next generation cancer therapeutics William R Sellers - Novartis Institutes of BioMedical Research - Cambridge, USA 4.30 - 5.00 p.m. Coffee Break 5.00 - 8.30 p.m. Poster session 	1.30 - 2.00 p.m.	
 3.00 - 3.30 p.m. Therapy of lymphoma inspired by functional and structural genomics Louis M Staudt - National Cancer Institute, Center for Cancer Research - Bethesda, USA 3.30 - 4.00 p.m. Pending Neal Rosen - Dept. of Medicine, Memorial Sloan Kettering Cancer Center - New York, USA 4.00 - 4.30 p.m. The development of next generation cancer therapeutics William R Sellers - Novartis Institutes of BioMedical Research - Cambridge, USA 4.30 - 5.00 p.m. Coffee Break 5.00 - 8.30 p.m. Poster session 	2.00 - 2.30 p.m.	Jeffrey A Sosman - Vanderbilt-Ingram Cancer Center, Vanderbilt Univ. Medical Center -
 Louis M Staudt - National Cancer Institute, Center for Cancer Research - Bethesda, USA 3.30 - 4.00 p.m. Pending Neal Rosen - Dept. of Medicine, Memorial Sloan Kettering Cancer Center - New York, USA 4.00 - 4.30 p.m. The development of next generation cancer therapeutics William R Sellers - Novartis Institutes of BioMedical Research - Cambridge, USA 4.30 - 5.00 p.m. Coffee Break 5.00 - 8.30 p.m. Poster session 	2.30 - 3.00 p.m.	Coffee Break
Neal Rosen - Dept. of Medicine, Memorial Sloan Kettering Cancer Center - New York, USA 4.00 - 4.30 p.m. The development of next generation cancer therapeutics William R Sellers - Novartis Institutes of BioMedical Research - Cambridge, USA 4.30 - 5.00 p.m. Coffee Break 5.00 - 8.30 p.m. Poster session	3.00 - 3.30 p.m.	
William R Sellers - Novartis Institutes of BioMedical Research - Cambridge, USA 4.30 - 5.00 p.m. Coffee Break 5.00 - 8.30 p.m. Poster session	3.30 - 4.00 p.m.	0
5.00 - 8.30 p.m. Poster session	4.00 - 4.30 p.m.	
	4.30 - 5.00 p.m.	Coffee Break
	5.00 - 8.30 p.m.	

Thursday - Dec. 08, 2016

Poster Presentation - Klenk Symposium 2016

We are pleased to announce the submission for poster abstracts related to the following topics:

- (A) Discovering basic principles of actionable genomic aberrations in cancer/tumor evolution/acquired resistance
- (B) Using mouse models as preclinical avatars for the development of precision cancer
- (C) Novel approaches for targeted intervention in solid tumors, lymphomas and leukemias
- (D) Immune checkpoint blockade as a novel therapeutic approach

The poster track is intended as a forum that provides an opportunity for the authors to present original research results, ongoing and preliminary results to promote interaction. For further information, please visit: Klenk Symposium 2016 - Poster presentation.

Poster Award

The Klenk Poster Award 2016 of the Center for Molecular Medicine Cologne (CMMC) will be awarded to the presenting author of the three most outstanding poster contributions. The awardees of the poster prize are invited to give a short presentation (10 min.) during the last session of the Klenk Symposium 2016.

Friday - Dec. 09, 2016

	Using mouse models as preclinical avatars for the development of precision cancer
9.00 - 9.30 a.m.	Mouse models of lung cancer; What do they teach us? Anton Berns – Netherlands Cancer Institute - Amsterdam, NLD
9.30 - 10.00 a.m.	The use of mouse lung cancer models for preclinical testing of novel targeted therapeutics Kwok Kin Wong Dana-Farber Cancer Institute, Harvard Medical School - Boston, USA
10.00 - 10.30 a.m.	Title pending Pier Paolo Pandolfi - Div. of Genetics, Beth Israel Deaconess Medical Center - Boston, USA
10.30 - 11.00 a.m.	Coffee Break
11.00 - 11.30 a.m.	Dissecting cancer drivers and dependencies in mouse models <u>Scott W Lowe</u> - Dept. of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center / Howard Hughes Med. Institutes - New York, USA
11.30 - 12.00 a.m.	Modeling and targeting GI-cancer subtypes <u>Dieter Saur</u> - II Med. Klinik und Poliklinik, Technische Universität München - Munich, GER
12.00 - 12.30 p.m.	Mouse models of small cell lung cancer to identify novel therapeutics strategies Julien Sage - Depts. of Pediatrics and Genetics, Stanford University Medical Center - Stanford, USA
12.30 - 2.00 p.m.	Lunch Break with Poster Presentation (sandwiches & sausages for all participants at the venue)
Session III	Novel approaches for targeted intervention in solid tumors, lymphomas and
	leukemias
2.00 - 2.30 p.m.	Being precise on the EGER pathway
2.30 - 3.00 p.m.	Being precise on the EGFR pathway <u>Tony S K Mok</u> - Dept. of Clinical Oncology of Sciences, Chinese University of Hong Kong - HK Lessons from targeted therapy in leukaemia and lymphoma
2.30 - 3.00 p.m.	Being precise on the EGFR pathway Tony S K Mok - Dept. of Clinical Oncology of Sciences, Chinese University of Hong Kong - HK Lessons from targeted therapy in leukaemia and lymphoma John G Gribben - Barts Cancer Center, Queen Mary University of London - London, UK Mechanisms of acquired resistance to third generation TKIs Enriqueta Felip - Institute of Oncology, Vall d'Hebron University Hospital - Barcelona, ESP
2.30 - 3.00 p.m. 3.00 - 3.30 p.m. 3.30 - 3.50 p.m.	Being precise on the EGFR pathway Tony S K Mok - Dept. of Clinical Oncology of Sciences, Chinese University of Hong Kong - HK Lessons from targeted therapy in leukaemia and lymphoma John G Gribben - Barts Cancer Center, Queen Mary University of London - London, UK Mechanisms of acquired resistance to third generation TKIs Enriqueta Felip - Institute of Oncology, Vall d'Hebron University Hospital - Barcelona, ESP
2.30 - 3.00 p.m. 3.00 - 3.30 p.m. 3.30 - 3.50 p.m. 3.50 - 4.00 p.m.	Being precise on the EGFR pathway <u>Tony S K Mok</u> - Dept. of Clinical Oncology of Sciences, Chinese University of Hong Kong - HK Lessons from targeted therapy in leukaemia and lymphoma John G Gribben - Barts Cancer Center, Queen Mary University of London - London, UK Mechanisms of acquired resistance to third generation TKIs <u>Enriqueta Felip</u> - Institute of Oncology, Vall d'Hebron University Hospital - Barcelona, ESP <i>Coffee Break</i>
2.30 - 3.00 p.m. 3.00 - 3.30 p.m. 3.30 - 3.50 p.m. 3.50 - 4.00 p.m.	Being precise on the EGFR pathway Tony S K Mok - Dept. of Clinical Oncology of Sciences, Chinese University of Hong Kong - HK Lessons from targeted therapy in leukaemia and lymphoma John G Gribben - Barts Cancer Center, Queen Mary University of London - London, UK Mechanisms of acquired resistance to third generation TKIs Enriqueta Felip - Institute of Oncology, Vall d'Hebron University Hospital - Barcelona, ESP Coffee Break Announcement of the Poster Awards - Christian Reinhardt and Roman Thomas Somatic alterations in non-small cell lung cancer genomes Matthew L Meyerson - Dana-Farber Cancer Center, Harvard Medical School - Boston, USA
2.30 - 3.00 p.m. 3.00 - 3.30 p.m. 3.30 - 3.50 p.m. 3.50 - 4.00 p.m. 4.00 - 4.30 p.m.	Being precise on the EGFR pathway Tony S K Mok - Dept. of Clinical Oncology of Sciences, Chinese University of Hong Kong - HK Lessons from targeted therapy in leukaemia and lymphoma John G Gribben - Barts Cancer Center, Queen Mary University of London - London, UK Mechanisms of acquired resistance to third generation TKIs Enriqueta Felip - Institute of Oncology, Vall d'Hebron University Hospital - Barcelona, ESP Coffee Break Announcement of the Poster Awards - Christian Reinhardt and Roman Thomas Somatic alterations in non-small cell lung cancer genomes Matthew L Meyerson - Dana-Farber Cancer Center, Harvard Medical School - Boston, USA Title pending Clemens A Schmitt - Charité - Universitätsmedizin and Max-Delbrück-Center for Molecular Medicine - Berlin, GER
2.30 - 3.00 p.m. 3.00 - 3.30 p.m. 3.30 - 3.50 p.m. 3.50 - 4.00 p.m. 4.00 - 4.30 p.m. 4.30 - 5.00 p.m. 5.00 - 5.30 p.m.	Being precise on the EGFR pathway Tony S K Mok - Dept. of Clinical Oncology of Sciences, Chinese University of Hong Kong - HK Lessons from targeted therapy in leukaemia and lymphoma John G Gribben - Barts Cancer Center, Queen Mary University of London - London, UK Mechanisms of acquired resistance to third generation TKIs Enriqueta Felip - Institute of Oncology, Vall d'Hebron University Hospital - Barcelona, ESP Coffee Break Announcement of the Poster Awards - Christian Reinhardt and Roman Thomas Somatic alterations in non-small cell lung cancer genomes Matthew L Meyerson - Dana-Farber Cancer Center, Harvard Medical School - Boston, USA Title pending Clemens A Schmitt - Charité - Universitätsmedizin and Max-Delbrück-Center for Molecular Medicine - Berlin, GER Title pending

Tracking Cancer Evolution : TRACERx Charles Swanton - The Francis Crick Institute - London, UK

Laudatio: Christian Reinhardt and Roman Thomas

Saturday - Dec. 10, 2016

Session IV Immune checkpoint blockade as a novel therapeutic approach

9.00 - 9.30 a.m.	Targeting immune recognition and regulation at the tumor site Sergio A Quezada - Cancer Immunology Unit, UCL Cancer Institute, UCL - London, UK
9.30 - 10.00 a.m.	Development and reversal of T cell exhaustion <u>E John Wherry</u> - Dept. of Microbiology and Institute for Immunology, University of Pennsylvania - Philadelphia, USA
10.00 - 10.30 a.m.	PD-1 cancer immunotherapy Gordon J. Freeman - Dept. of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School - Boston, USA
10.30 - 11.00 a.m.	Coffee Break
11.00 - 11.30 a.m.	Checkpoint blockade in Melanoma: what do we know? <u>Dirk Schadendorf</u> - Dept. of Dermatology, Venerology and Allergology, University Hospital - Essen, GER
11.30 - 12.00 p.m.	Single-agent beyond inhibitor checkpoint in cancer immunotherapy <u>William Pao</u> - Oncology Translational Medicine, Roche Pharma Research and Early Development - Basel, CHE
12.00 - 12.30 p.m.	Resistance mechanisms in cancer immunotherapy <u>Thomas Tüting</u> - Dept. of Dermatology, University Hospital - Magdeburg, GER
12.30 - 1.00 p.m.	Short presentation of the three poster awardees (3 x 10 min. short talk)
1.00 - 1.15 p.m.	Summary, open questions, concluding remarks Charles Swanton - Christian Reinhardt - Roman Thomas
For further	information chart anonacring activities

For further information about sponsoring activities: please contact Prof. Dr. C Reinhardt (<u>christian.reinhardt@uk-koeln.de</u>) or Prof. Dr. Roman Thomas (<u>roman.thomas@uni-koeln.de</u>)

General Information

The meeting is open and no registration or attendance fee is required. Participation is free of charge - free registration is required. Childcare is provided by Spielland, University Hospital Cologne: please contact D. Grosskopf-Kroiher for further information.

Contact Address:

Debora Grosskopf-Kroiher Center for Molecular Medicine Cologne (CMMC), University of Cologne CMMC Research Building, Robert-Koch-Str. 21, 50931 Cologne, Germany Phone: +49 (0)221 478 5552, Fax: +49 (0)221 478 4833 / E-mail: <u>debora.grosskopf-kroiher@uni-koeln.de</u>

We gratefully acknowledge support by following industrial sponsors (current state June 2016):



If you are interested to support the Klenk Symposium 2016, please contact Christian Reinhardt or Roman Thomas.